After a challenging year for Sarepta Therapeutics, its chief executive has received his first equity grant in about eight ...

Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.

Investing.com -- Sarepta Therapeutics Inc (NASDAQ:SRPT) stock fell 3.7% on Thursday after the company announced a debt exchange agreement that will restructure a portion of its convertible notes.

Investing.com -- Sarepta Therapeutics (NASDAQ:SRPT) stock fell 8% on Thursday after the rare disease medicine specialist announced it would refinance approximately $291 million of its convertible ...

Sarepta Therapeutics ( ($SRPT) ) has issued an announcement. On December 10, 2025, Sarepta Therapeutics entered into exchange agreements to ...

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a limited ...

Becker is a serious, progressive neuromuscular condition that is X-linked, affecting approximately one in 18,000 male ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics (NASDAQ:SRPT) leads in genetic therapies, contributing to ongoing discussions surrounding the nasdaq ...

Sarepta Therapeutics (SRPT) has quietly staged a sharp rebound over the past month, even though the longer term chart still looks bruised. That mix of momentum and past damage naturally raises ...

Wondering if Sarepta Therapeutics is a beaten down biotech bargain or a value trap? This article will walk through the numbers in plain English so you can decide with confidence. Despite a brutal long ...

Fintel reports that on December 9, 2025, Wedbush initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Outperform ...